KalVista Pharmaceuticals Inc. (NASDAQ:KALV) on Thursday reported early commercial momentum for its hereditary angioedema treatment EKTERLY, highlighting growing prescriber adoption, repeat prescriptions and expanding global access following its mid-2025 launch. • KalVista Pharmaceuticals stock is approaching key resistance levels. Why did KALV hit a new high?In July 2025, the U.S. Food and Drug Administration (FDA) approved Ekterly for acute attacks of hereditary angioedema (HAE) in adult and pediatric pati ...

KalVista Pharmaceuticals Corporate Overview January 2026 1 Forward-looking statements This presentation and the accompanying oral commentary contain forward-looking statements that are based on our management's beliefs and assumptions and on information currently available to our management. For this purpose, any statements that are not statements of historical fact may be deemed forward-looking statements. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be ...